Mereo BioPharma Group (MREO) News Today $2.41 +0.04 (+1.69%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$2.46 +0.05 (+2.24%) As of 03/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Mereo BioPharma Group (NASDAQ:MREO) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.March 28 at 3:15 AM | americanbankingnews.comMereo BioPharma initiated with an Overweight at JPMorganMarch 27 at 6:16 PM | markets.businessinsider.comCantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)March 27 at 6:16 PM | markets.businessinsider.comJP Morgan Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Overweight RecommendationMarch 27 at 6:16 PM | msn.comMereo BioPharma Group's (MREO) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Wednesday.March 27 at 11:41 AM | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Releases Earnings Results, Misses Estimates By $0.03 EPSMereo BioPharma Group (NASDAQ:MREO - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03).March 27 at 9:12 AM | marketbeat.comMereo BioPharma sees cash runway into 2027March 27 at 8:15 AM | markets.businessinsider.comMereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLCMarch 27 at 3:45 AM | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Allurion Technologies (ALUR), Savara (SVRA)March 27 at 3:14 AM | markets.businessinsider.comMereo BioPharma Group plc: Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate HighlightsMarch 26 at 10:22 AM | finanznachrichten.deMereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate HighlightsMarch 26 at 7:30 AM | globenewswire.comMereo BioPharma’s SWOT analysis: setrusumab, alvelestat drive rare disease stock potentialMarch 21, 2025 | uk.investing.comMereo BioPharma Group (NASDAQ:MREO) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Mereo BioPharma Group in a report on Tuesday.March 19, 2025 | marketbeat.comTejara Capital Ltd Reduces Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)Tejara Capital Ltd decreased its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 18.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,317,085 shares of the company's stock after selling 5March 19, 2025 | marketbeat.comMereo BioPharma Group's (MREO) Overweight Rating Reiterated at Cantor FitzgeraldMarch 19, 2025 | americanbankingnews.comMereo BioPharma Group (MREO) to Release Quarterly Earnings on WednesdayMereo BioPharma Group (NASDAQ:MREO) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comBrokerages Set Mereo BioPharma Group plc (NASDAQ:MREO) PT at $7.83March 19, 2025 | americanbankingnews.comMereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Rating of "Buy" from BrokeragesMereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and three have given a strong buy recommendMarch 16, 2025 | marketbeat.comMereo BioPharma management to meet with Cantor FitzgeraldMarch 11, 2025 | markets.businessinsider.comHidden Gems: 5 Stocks Under $10 With Massive Growth Potential (MREO)Uncover five promising stocks under $10, each poised for gains across diverse sectors for the second quarter of 2025.March 11, 2025 | marketbeat.comMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comHealthInvest Partners AB Has $1.37 Million Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)HealthInvest Partners AB lifted its position in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 95.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,000 shares of the coFebruary 24, 2025 | marketbeat.comAptos Price Forecast: APT and Mereo partnership fuels investors’ optimism as K-Pop fan engagement evolvesFebruary 20, 2025 | fxstreet.comMereo BioPharma Group plc (NASDAQ:MREO) Given Average Rating of "Buy" by BrokeragesMereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and three have given a strong buy ratingFebruary 19, 2025 | marketbeat.comMereo BioPharma: Good Science, Fairly ValuedFebruary 11, 2025 | seekingalpha.comMereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Recommendation of "Buy" from AnalystsShares of Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) have been given an average rating of "Buy" by the seven analysts that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating and three have given a strong buy rating toJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Comments on MREO FY2024 EarningsMereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Mereo BioPharma Group in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0January 23, 2025 | marketbeat.comOptimism in Mereo Biopharma: Strong Phase II Results and Strategic Advancements Fuel Buy RatingJanuary 15, 2025 | markets.businessinsider.comMereo Biopharma’s Strategic Progress and Promising Pipeline Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Mereo Biopharma Group Plc (MREO)January 14, 2025 | markets.businessinsider.comMereo BioPharma Group (NASDAQ:MREO) Sets New 52-Week Low - Here's WhyMereo BioPharma Group (NASDAQ:MREO) Sets New 52-Week Low - Here's WhyJanuary 14, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Shares Gap Down - What's Next?Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Down - What's Next?January 13, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a report on Monday.January 13, 2025 | marketbeat.comMereo BioPharma Group plc: Mereo BioPharma Provides Update on Lead Clinical ProgramsJanuary 13, 2025 | finanznachrichten.deMereo BioPharma Provides Update on Lead Clinical ProgramsJanuary 12, 2025 | globenewswire.comMereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comMereo BioPharma Group plc (NASDAQ:MREO) Receives Average Recommendation of "Buy" from BrokeragesShares of Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and three have issued a strong buy recommDecember 31, 2024 | marketbeat.comWhy Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comMereo BioPharma Group (NASDAQ:MREO) Stock Price Down 2.6% - Here's WhyMereo BioPharma Group (NASDAQ:MREO) Stock Price Down 2.6% - Time to Sell?December 26, 2024 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Upgraded by Lifesci Capital to Strong-Buy RatingLifesci Capital upgraded shares of Mereo BioPharma Group to a "strong-buy" rating in a report on Monday.December 25, 2024 | marketbeat.comLifeSci Capital Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Outperform RecommendationDecember 25, 2024 | msn.comMereo BioPharma Group (NASDAQ:MREO) Shares Gap Up - Time to Buy?Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up - What's Next?December 24, 2024 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Now Covered by Lifesci CapitalLifesci Capital started coverage on shares of Mereo BioPharma Group in a research note on Tuesday. They set an "outperform" rating and a $10.00 price target on the stock.December 24, 2024 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Hits New 1-Year Low - Should You Sell?Mereo BioPharma Group (NASDAQ:MREO) Sets New 12-Month Low - Here's What HappenedDecember 20, 2024 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Sees Strong Trading Volume - What's Next?Mereo BioPharma Group (NASDAQ:MREO) Sees Strong Trading Volume - What's Next?December 18, 2024 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Stock Price Down 4.5% - Time to Sell?Mereo BioPharma Group (NASDAQ:MREO) Shares Down 4.5% - What's Next?December 16, 2024 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Raised to Strong-Buy at Cantor FitzgeraldCantor Fitzgerald upgraded Mereo BioPharma Group to a "strong-buy" rating in a report on Sunday.December 10, 2024 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Shares Purchased by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. boosted its holdings in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 15.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,097,779 shares of thDecember 10, 2024 | marketbeat.comMereo Biopharma Group Plc: Strong Buy Rating Due to Promising Pipeline and Strategic PartnershipsDecember 6, 2024 | markets.businessinsider.comJefferies Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Buy RecommendationDecember 6, 2024 | msn.com Remove Ads Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address MREO Media Mentions By Week MREO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MREO News Sentiment▼-0.060.78▲Average Medical News Sentiment MREO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MREO Articles This Week▼152▲MREO Articles Average Week Remove Ads Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMCR News Today ANIP News Today DYN News Today INDV News Today AMPH News Today ETNB News Today ADPT News Today EVO News Today SPRY News Today ARDX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MREO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
